您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > ALG1001 TFA
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ALG1001 TFA
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ALG1001 TFA图片
CAS NO:1307293-62-4
规格:≥98%

产品介绍
理化性质和储存条件
Molecular Weight (MW) 751.68
Formula C22H39N9O11S TFA
CAS No. 1307293-62-4 (free base)
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO:>10 mM
Water: >10 mM
Ethanol:
Chemical Name L-Proline, glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl- Trifluoroacetic acid
Synonyms Luminate; H-Gly-Arg-Gly-(L-Ala(SO3))-Thr-Pro-OH; ALG1001; ALG-1001; ALG 1001
SMILES Code O=C(O)[C@H]1N(C([C@H]([C@H](O)C)NC([C@H](CS(=O)(O)=O)NC(CNC([C@H](CCCNC(N)=N)NC(CN) =O)=O)=O)=O)=O)CCC1.O=C(O)C(F)(F)F
实验参考方法
In Vitro

In vitro activity: ALG1001 (also known as Luminate, developed by Allegro Ophthalmics) is small peptide that acts as an inhibitor of angiogenesis and a modulator of integrin α2ss1, αV-ss 3, αV-ss 5. ALG-1001 is a first-in-class integrin peptide therapy which met the primary endpoint of vision non-inferiority to bevacizumab, an anti-vascular endothelial growth factor therapy (anti-VEGF), with 12-week durability in a population of patients with mostly chronic diabetic macular edema (DME). ALG1001's potency relies on anti-angiogenesis and vitreolysis to induce posterior vitreous detachment as well as vitreous liquefaction. ALG1001 was shown to be effective at regressing and inhibiting new blood vessel formation, as well as reducing vascular leakage to maintain and restore vision. ALG-1001 seems to be a strong player with different mechanisms of action that benefit patients who have been receiving chronic anti-VEGF therapy and those who are treatment naive.


Kinase Assay: ALG-1001 binds to the retinal pigment epithelium for several months.


Cell Assay: ALG-1001 reduced vascular leakage. Other investigations have shown that the formulation affects only stressed retinal cells and has an anti-inflammatory effect,

In VivoALG-1001 appeared to have 4 times more anti-angiogenic activity compared with aflibercept (Eylea, Regeneron Pharmaceuticals) in a murine model of retinopathy of prematurity.
Animal model
Formulation & Dosage
References US 20130129621 A1 20130523; WO 2012154894 A2 20121115.